Artelo Biosciences, Inc. Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
February 16, 2021 at 07:00 pm IST
Share
Artelo Biosciences, Inc. announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR®, FORXIGA®, and KEYTRUDA®. In this new role at Artelo, Dr. Yates will be responsible for advancing the Company’s research and development, oversee engagement with the Scientific Advisory Board, and serve as a key member of Artelo’s executive management team. Dr. Yates is a registered pharmacist in the UK who served more than a decade as a senior executive at AstraZeneca where he was responsible for strategic development of the cardiovascular and diabetes internal portfolio, including the acquisition of Bristol Myers Squib’s diabetes pipeline, and architecting the overall approach and expansion to novel technologies in areas such as gene therapy. He has an established and successful track record of partnership and collaborative agreements with academia, biotechnology and peer pharma companies.
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.